SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.
Portfolio Pulse from
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) has received FDA approval for its new product, ArbliTM, a losartan potassium oral suspension. This is the first FDA-approved ready-to-use oral liquid losartan in the U.S., targeting hypertension, stroke risk reduction, and diabetic nephropathy.
March 18, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) has received FDA approval for ArbliTM, a novel losartan potassium oral suspension. This approval positions SCNX to capture a share of the $1.5 billion global losartan market, potentially boosting its stock price.
The FDA approval of ArbliTM, a unique product in the U.S. market, is likely to positively impact SCNX's stock price. The product addresses significant medical needs and enters a substantial market, suggesting potential revenue growth.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100